Xerostomia (Dry Mouth) Therapeutics - Global Strategic Business Report

The global market for Xerostomia (Dry Mouth) Therapeutics was valued at US$684 Million in 2025 and is projected to reach US$818.4 Million by 2032, growing at a CAGR of 2.6% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Xerostomia (Dry Mouth) Therapeutics Market - Key Trends and Drivers Summarized

Xerostomia, commonly known as dry mouth, is a condition characterized by a decrease in saliva production, which can lead to various complications such as difficulty in swallowing, dental decay, and oral infections. This condition can arise from multiple sources including side effects from certain medications, underlying medical issues, exposure to radiation therapy, and natural aging processes. Xerostomia therapeutics encompass a range of treatments designed to alleviate these symptoms and restore moisture to the mouth. These treatments include saliva substitutes, oral moisturizers, medications that stimulate saliva production, and lifestyle changes aimed at enhancing oral hydration.

The demand for xerostomia therapeutics is primarily driven by the rising prevalence of chronic diseases such as diabetes, Sjögren's syndrome, and Parkinson's disease, which are commonly associated with dry mouth. An aging global population, which is more susceptible to these chronic conditions, further compounds the demand for effective treatments. Additionally, the increasing awareness and diagnosis of xerostomia, coupled with improvements in healthcare infrastructure that allow for better management of symptoms associated with the condition, also contribute to the growth of the market. The pharmaceutical development of new agents that can effectively stimulate saliva production without significant side effects is another significant driver that is likely to spur the demand for these therapeutics.

Recent trends in the xerostomia therapeutics market include the development of more advanced formulation technologies and drug delivery systems designed to improve the efficacy and convenience of treatments. For example, the use of mucoadhesive agents that can be applied directly to the mucosa for prolonged action and enhanced symptom relief is gaining traction. There is also a noticeable shift towards natural and herbal remedies, reflecting a broader consumer preference for organic and less invasive treatment options. On the regulatory front, there is increased support for the research and development of innovative therapeutics, facilitated by grants and approvals from bodies such as the FDA, which streamline the pathway for bringing new treatments to market. In recent developments, innovative treatments like glandular regeneration and gene therapy have shown promise, particularly for patients who have developed xerostomia as a consequence of radiation therapy. These cutting-edge approaches aim to restore normal function to the salivary glands, offering hope for a more permanent solution to the challenges posed by xerostomia. As research continues to advance, these therapies highlight the progressive shift towards more targeted and regenerative treatment strategies in the management of dry mouth, aligning with broader trends in medical science that emphasize restoration and healing at a cellular level.

Report Scope

The report analyzes the Xerostomia (Dry Mouth) Therapeutics market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Type (Over-the-Counter, Prescription); Product Segment (Dentifrices, Salivary Stimulants, Salivary Substitutes).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Over-the-Counter segment, which is expected to reach US$488.8 Million by 2032 with a CAGR of a 2.7%. The Prescription segment is also set to grow at 2.4% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $186.4 Million in 2025, and China, forecasted to grow at an impressive 4.6% CAGR to reach $157.1 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Xerostomia (Dry Mouth) Therapeutics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Xerostomia (Dry Mouth) Therapeutics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Xerostomia (Dry Mouth) Therapeutics Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as 3M Company, Bausch Health Companies Inc., Dentaid SL, Dr. Reddy's Laboratories Ltd., Forward Science and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Xerostomia (Dry Mouth) Therapeutics market report include:

• 3M Company
• Bausch Health Companies Inc.
• Dentaid SL
• Dr. Reddy's Laboratories Ltd.
• Forward Science
• GC America, Inc.
• ICPA Health Pvt. Ltd.
• Laclede, Inc.
• Livealth Biopharma Pvt Ltd.
• Malo Clinic, S.A.

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.